7200AA23RFA00002: HIV Vaccine Innovation, Science, and Technology Acceleration in Africa (HIV-VISTA)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of Agency for International Development notices from 2022.
Agency for International Development offered grants of up to $46.0 million (at least $46.0 million) to nonprofits, colleges and universities and businesses. It expected to make about 2 awards. Applications closed on May 31, 2023.
From the official notice on Grants.gov, last changed April 10, 2023. Checked November 7, 2026.
- Award ceiling$46.0 million
- Award floor$46.0 million
- Expected awards2
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | November 17, 2022 |
|---|---|
| Deadline | May 31, 2023 |
| Archived by Grants.gov | June 2, 2023 |
Who can apply
This opportunity was open to nonprofits, colleges and universities and businesses.
All 6 applicant types the notice lists
- Public and State controlled institutions of higher education
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Eligibility for this NOFO is restricted to local entities in African countries, using the definition of “local entity” in the PEPFAR 2022 Country and Regional Operational Plan (COP/ROP). Per this guidance, local entity is defined as “an entity other than a sole proprietorship (such as a corporation or not-for-profit) must meet all three areas of eligibility:(1) EITHER, must be incorporated or legally organized under the laws of, and have its principal place of business in, the country or a country in the region served by the PEPFAR program with which the entity is or may become involved; OR must exist in the region where PEPFAR programs are implemented;(2) EITHER, must be at 75% beneficially owned at the time of application by individuals who are citizens or lawfully admitted permanent residents of that same country; OR at least 75% of the entity’s staff (senior, mid-level, support) at the time of application must be citizens or lawfully admitted permanent residents of that same country; (3) Where an entity has a Board of Directors, at least 51% of the members of the Board must also be citizens or lawfully admitted permanent residents of such country.
Is this a realistic fit?
- Past USAID Foreign Assistance for Programs Overseas awards averaged $8.7 million; this notice allows up to $46.0 million per award.
- Most of the program's money (54% over five years) went to nonprofits.
- No cost sharing or match is required.
What the grant funds
The objective of the HIV-VISTA Project is to support sub-Saharan African scientists, institutions, and innovative systems of collaboration in designing and testing improved HIV vaccine candidates that will advance the field toward the long-term goal of a safe and globally-effective HIV vaccine. Activities should be implemented in at least three different countries in sub-Saharan African Closing Date and Time for CONCEPT NOTE: Friday January 20, 2023; 4:00 PM, Washington DC local time Closing Date and Time for FULL APPLICATION (INVITATION ONLY): Wednesday May 31, 2023; at 4:00 PM, Washington DC local time Note: All Applicants that fit the Eligibility criteria are welcome to submit concept notes. At the concept stage, please submit proof documentation the eligibility. However, request for Full Application will be based on invitation. Therefore in order to be considered, all eligible Applicants interested must submit concept note by deadline to be considered for co-creation and Full Application. Please download and read all the relevant documents especially the NOFO Amendment 2 to understand the process. (UPDDATE APRIL 10, 2023: The process for concept notes has been closed.)
Who has won USAID Foreign Assistance for Programs Overseas grants before
From fiscal 2021 to 2025, USAID Foreign Assistance for Programs Overseas (98.001) awarded $37 billion across 4,233 grant awards, an average of $8.7 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Miscellaneous Foreign Awardees | District of Columbia | 489 | $6.9 billion |
| Family Health International | North Carolina | 91 | $2.1 billion |
| Catholic Relief Services - United States Conference of Catholic Bishops | Maryland | 128 | $1.2 billion |
| Save the Children Federation, Inc. | Connecticut | 100 | $814 million |
| Research Triangle Institute | North Carolina | 33 | $756 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is 7200AA23RFA00002 still open?
No. It closed on May 31, 2023.
Who can apply for HIV Vaccine Innovation, Science, and Technology Acceleration in Africa (HIV-VISTA)?
Agency for International Development accepted applications from nonprofits, colleges and universities and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for HIV Vaccine Innovation, Science, and Technology Acceleration in Africa (HIV-VISTA)?
Closed May 31, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $46.0 million each.
Who has won USAID Foreign Assistance for Programs Overseas grants before?
The largest recipients over five fiscal years were Miscellaneous Foreign Awardees, Family Health International, Catholic Relief Services - United States Conference of Catholic Bishops. The program made 4,233 awards worth $37 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)